New research has found that high risk and minority women receive better cancer care if they are paired with a patient navigator.
New research has found that high risk and minority women receive better cancer care if they are paired with a patient navigator.
The study, published in the Journal of Clinical Oncology, found that navigated participants were more likely than non-navigated participants to receive antiestrogen therapy, which is considered the gold standard in treatment for certain types of breast cancer.
“This study gave us a glimpse of the potential benefit of patient navigation but there’s a lot more research to be done,” Naomi Ko, MD, MPH, instructor of medicine in the Section of Hematology Oncology at Boston University School of Medicine and a practicing breast oncologist at Boston Medical Center said in a statement. “At this point we still need to understand how or why patient navigation works.”
Using data from a previously published, multicenter study funded by the National Cancer Institute, researchers aimed to identify the possible benefits of assigning patient navigators to women recently diagnosed with breast cancer.
The results showed that among participants eligible for antiestrogen therapy, navigated participants (n = 380) had a statistically significant higher likelihood of receiving antiestrogen therapy compared with non-navigated controls (n = 381; odds ratio [OR], 1.73; P = .004) in a multivariable analysis.
However, the results of the analysis also found that navigated participants eligible for radiation therapy after lumpectomy (n = 255) were no more likely to receive radiation (OR, 1.42; P = .22) than control participants (n = 297).
“Understanding where patient navigation is most beneficial in cancer care, in order to help the neediest patients, is a rich topic for future research, “ Ko said.
Navigators are experts in helping patients overcome the numerous obstacles they face, including monetary difficulties, transportation issues, educational and even language barriers, and have become an integral part of the cancer care model. It has been known that minority and high-risk patients, or those who may benefit most from these navigators, often have worse outcomes after diagnosed with cancer.
Reference
Ko NY, Darnell JS, Calhoun E, et al. Can patient navigation improve receipt of recommended breast cancer care? Evidence from the National Patient Navigation Research Program [published online ahead of print July 28, 2014]. J Clin Oncol.
Workflow, Educational Tools Improve Use of Silicone Film to Prevent Radiation Dermatitis
April 25th 2024Tools to educate oncology nurses and patients on the use of Mepitel film to prevent radiation dermatitis has improved the workflow around its introduction to patients with breast cancer, as well as its application and maintenance.
Olaparib Plus Chemo May Not Improve Outcomes vs Chemo Alone in BRCA Wild-Type TNBC
April 23rd 2024Patients with BRCA wild-type triple-negative breast cancer treated with olaparib on a gap schedule with chemotherapy did not experience improved responses compared with chemotherapy alone in the neoadjuvant setting.
Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium
January 16th 2023Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.
Workflow, Educational Tools Improve Use of Silicone Film to Prevent Radiation Dermatitis
April 25th 2024Tools to educate oncology nurses and patients on the use of Mepitel film to prevent radiation dermatitis has improved the workflow around its introduction to patients with breast cancer, as well as its application and maintenance.
Olaparib Plus Chemo May Not Improve Outcomes vs Chemo Alone in BRCA Wild-Type TNBC
April 23rd 2024Patients with BRCA wild-type triple-negative breast cancer treated with olaparib on a gap schedule with chemotherapy did not experience improved responses compared with chemotherapy alone in the neoadjuvant setting.
Nurse Practitioners Weigh in on Data From the San Antonio Breast Cancer Symposium
January 16th 2023Loyda Braithwaite, MSN, RN, AGPCNP-BC, AOCNP; and Jamie Carroll, APRN, CNP, MSN, highlight presentations from the 2022 San Antonio Breast Cancer Symposium that will influence oncology nursing practice.
Workflow, Educational Tools Improve Use of Silicone Film to Prevent Radiation Dermatitis
Inconsistent Symptom Clusters Warrant Routine Assessments in Older Patients With Cancer
Olaparib Plus Chemo May Not Improve Outcomes vs Chemo Alone in BRCA Wild-Type TNBC
Less Than Half of Recently Approved Cancer Drugs Show a Clinical Benefit
2 Commerce Drive
Cranbury, NJ 08512